Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses

Molecular Therapy

Volumn 5, Issue 3, 2002, Pages 233-241

  Yotnda, Patricia ^a   Chen, Dong Hua ^b   Chiu, Wah ^b   Piedra, Pedro A ^b   Davis, Alan ^a   Templeton, Nancy Smyth ^a   Brenner, Malcolm K ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adenovirus; DOTAP:chol; Encapsulation; Gene therapy; Lung; Readministration

Indexed keywords

1,2 DIOLEOYLOXYPROPYL TRIMETHYLAMMONIUM CHLORIDE; ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; BETA GALACTOSIDASE; CATION; CHOLESTEROL; HUMORAL ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; NEUTRALIZING ANTIBODY; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; COXSACKIE VIRUS; CRYOELECTRON MICROSCOPY; ENCAPSULATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENETIC CODE; GENETIC RESISTANCE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VIVO STUDY; MOUSE; NONHUMAN; TARGET CELL;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS;

EID: 0036198993     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0545     Document Type: Article

References (52)

1. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
2. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
3. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung
4. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: A phase I clinical trial
5. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products
6. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients
7. Cystic fibrosis gene therapy using an adenovirus vector: In vivo safety and efficacy in nasal epithelium
8. A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis
9. Adenovirus as an expression vector in muscle cells in vivo
10. Cystic fibrosis. Vehicles for gene therapy
11. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA
12. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
13. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2
14. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
15. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
16. Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms
17. Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced lg subclass shifts
18. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon
19. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung
20. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4lg
21. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors
22. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression
23. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
24. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
25. Enhancement of adenoviral transduction with polycationic liposomes in vivo
26. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo
27. Improved DNA: Liposome complexes for increased systemic delivery and gene expression
28. Mechanism of enhancement of DNA expression consequent to cointernalization of a replication-deficient adenovirus and unmodified plasmid DNA
29. Complexes between cationic liposomes and DNA visualized by cryo-TEM
30. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans
31. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes
32. An electron microscopy study into the mechanism of gene transfer with lipopolyamines
33. Cellular and molecular barriers to gene transfer by a cationic lipid
34. Regulation of gene expression in vivo by liposome-mediated delivery of a purified transcription factor
35. Stepwise dismantling of adenovirus 2 during entry into cells
36. Mechanism of adenovirus improvement of cationic liposome-mediated gene transfer
37. Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and α(v)-integrins
38. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration
39. Inmune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity
40. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung
41. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo
42. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity
43. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
44. Immune responses to adenovirus and adeno-associated virus in humans
45. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages
46. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung
47. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection
48. Cryo-electron microscopy of vitrified specimens
49. Cofilin changes the twist of F-actin: Implications for actin filament dynamics and cellular function
50. EMAN: Semiautomated software for high-resolution single-particle reconstructions
51. Expression of human α 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes
52. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors